
According to Benzinga Pro, during Q4, Royalty Pharma (NASDAQ:RPRX) earned $53.67 million, a 75.8% increase from the preceding quarter. Royalty Pharma's sales decreased to $576.00 million, a 1.67% change since Q3. In Q3, Royalty Pharma earned $221.80 million, and total sales reached $585.77 million.